Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD.

OBJECTIVES Macrophage-mannose receptor, CD206, is a marker of alternatively activated macrophages. Activated macrophages play key roles in DM. Interstitial lung disease (ILD) is a leading cause of mortality in patients with DM/clinically amyopathic DM (CADM). In particular, patients with the anti-melanoma differential gene 5 antibody (MDA5) frequently develop fatal rapid progressive ILD. This study aimed to evaluate the clinical implications of alternatively activated macrophages in patients with CADM/DM-ILD with anti-MDA5 antibody (MDA5-CADM/DM-ILD). METHODS We measured serum concentrations of soluble CD206 (sCD206) in 33 patients with MDA5-CADM/DM-ILD and 36 age- and sex-matched control subjects. Expression levels of CD206 in the lungs from MDA5-CADM/DM-ILD were also examined. RESULTS Patients with MDA5-CADM/DM-ILD had higher levels of sCD206 than those in controls (P < 0.0001). Of the 33 patients, 10 MDA5-CADM/DM-ILD patients developed fatal respiratory failure. Concentrations of sCD206 in patients with fatal ILD cases were significantly higher than those in the survivors, and increased sCD206 levels were associated with a higher mortality rate (Log-rank test, P = 0.0009). Age- and gender-adjusted logistic regression analyses showed that sCD206 was an independent prognostic factor for MDA5-CADM/DM-ILD. Importantly, assessment by sCD206 together with PaO2 successfully divided into three groups by their prognosis (P < 0.005, respectively). Pathological analyses showed accumulations of CD206-positive macrophages in lungs from the fatal case rather than those in the non-fatal cases. CONCLUSIONS Levels of serum sCD206 are increased in MDA5-CADM/DM-ILD and associated with poor prognosis. sCD206 is a potential biomarker to predict the severity of MDA5-CADM/DM-ILD.

[1]  N. Inui,et al.  Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody–positive Dermatomyositis-associated Interstitial Lung Disease , 2019, The Journal of Rheumatology.

[2]  W. Gu,et al.  Macrophages: friend or foe in idiopathic pulmonary fibrosis? , 2018, Respiratory Research.

[3]  N. Inui,et al.  Macrophage mannose receptor, CD206, predict prognosis in patients with pulmonary tuberculosis , 2018, Scientific Reports.

[4]  Takeshi Johkoh,et al.  Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline , 2018, American journal of respiratory and critical care medicine.

[5]  T. Mimori,et al.  Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease , 2017, Arthritis Research & Therapy.

[6]  T. Mimori,et al.  Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. , 2016, Respiratory medicine.

[7]  D. Lynch,et al.  Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. , 2016, American journal of respiratory and critical care medicine.

[8]  M. Fujimoto,et al.  Clinical Utility of an Enzyme-Linked Immunosorbent Assay for Detecting Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies , 2016, PloS one.

[9]  R. Kolde,et al.  Flow Cytometric Analysis of Mononuclear Phagocytes in Nondiseased Human Lung and Lung-Draining Lymph Nodes. , 2016, American journal of respiratory and critical care medicine.

[10]  S. Mathai,et al.  Management of interstitial lung disease associated with connective tissue disease , 2016, BMJ : British Medical Journal.

[11]  Shandra L. Protzko,et al.  An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. , 2015, American journal of respiratory and critical care medicine.

[12]  T. Mimori,et al.  Prognostic Significance of Anti-Aminoacyl-tRNA Synthetase Antibodies in Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease: A Retrospective Case Control Study , 2015, PloS one.

[13]  D. Hashimoto,et al.  Prognostic Factors for Myositis-Associated Interstitial Lung Disease , 2014, PloS one.

[14]  T. Hussell,et al.  Alveolar macrophages: plasticity in a tissue-specific context , 2014, Nature Reviews Immunology.

[15]  Murugesan V. S. Rajaram,et al.  Exploitation of the Macrophage Mannose Receptor (CD206) in Infectious Disease Diagnostics and Therapeutics. , 2014, Journal of cytology & molecular biology.

[16]  F. Ginhoux,et al.  Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. , 2013, Immunity.

[17]  L. Martínez-Pomares.  The mannose receptor , 2012, Journal of leukocyte biology.

[18]  G. Verleden,et al.  The pathogenesis of pulmonary fibrosis: a moving target , 2012, European Respiratory Journal.

[19]  H. Yamanaka,et al.  Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. , 2012, Rheumatology.

[20]  H. Yamanaka,et al.  Hyperferritinaemia and macrophage activation in a patient with interstitial lung disease with clinically amyopathic DM. , 2012, Rheumatology.

[21]  L. Mouthon,et al.  Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. , 2011, Arthritis and rheumatism.

[22]  S. Forbes,et al.  Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis. , 2011, American journal of respiratory and critical care medicine.

[23]  T. Mimori,et al.  HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. , 2011, Respiratory medicine.

[24]  M. Fujimoto,et al.  Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. , 2011, Archives of dermatology.

[25]  T. Mimori,et al.  Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. , 2010, Rheumatology.

[26]  H. Yamanaka,et al.  Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. , 2010, Rheumatology.

[27]  S. Gordon,et al.  Alternative activation of macrophages: mechanism and functions. , 2010, Immunity.

[28]  K. Ohmura,et al.  The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. , 2010, Rheumatology.

[29]  S. Gringhuis,et al.  Signalling through C-type lectin receptors: shaping immune responses , 2009, Nature Reviews Immunology.

[30]  T. Fujita,et al.  RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. , 2009, Arthritis and rheumatism.

[31]  K. Chida,et al.  Intravenous Immunoglobulin Therapy for Refractory Interstitial Lung Disease Associated with Polymyositis/Dermatomyositis , 2009, Lung.

[32]  T. Kasama,et al.  Clinical features of hemophagocytic syndrome in patients with dermatomyositis. , 2008, The Journal of rheumatology.

[33]  M. Fritzler,et al.  Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes , 2007, Arthritis research & therapy.

[34]  K. Chida,et al.  Interstitial lung diseases associated with amyopathic dermatomyositis , 2006, European Respiratory Journal.

[35]  K. Ishii,et al.  Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses , 2006, Nature.

[36]  Antje Prasse,et al.  A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. , 2006, American journal of respiratory and critical care medicine.

[37]  A. Silman,et al.  In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype , 2005, Arthritis research & therapy.

[38]  R. Dwek,et al.  Glycosylation Influences the Lectin Activities of the Macrophage Mannose Receptor* , 2005, Journal of Biological Chemistry.

[39]  T. Nishikawa,et al.  Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. , 2005, Arthritis and rheumatism.

[40]  N. Miyasaka,et al.  Polymyositis/dermatomyositis and interstitial lung disease: A new therapeutic approach with T-cell-specific immunosuppressants , 2005, Autoimmunity.

[41]  V. Cottin,et al.  Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis , 2003, European Respiratory Journal.

[42]  Richard J. Stillion,et al.  Recognition of Bacterial Capsular Polysaccharides and Lipopolysaccharides by the Macrophage Mannose Receptor* , 2002, The Journal of Biological Chemistry.

[43]  D. Isenberg,et al.  Autoantibody profiles in the sera of European patients with myositis , 2001, Annals of the rheumatic diseases.

[44]  S. Madaule,et al.  Fatal haemophagocytic syndrome in the course of dermatomyositis with anti-Mi2 antibodies. , 2000, Rheumatology.

[45]  A. Bohan,et al.  Polymyositis and dermatomyositis (second of two parts). , 1975 .

[46]  T. Kurita,et al.  The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. , 2015, Rheumatology.

[47]  F. Ernste,et al.  Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. , 2013, Mayo Clinic proceedings.

[48]  H. Uchiyama,et al.  Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. , 2005, The Journal of rheumatology.